Carbimazole methimazole study

Not Applicable

Terminated

• Conditions: Graves' thyrotoxicosis

• Registration Number: SLCTR/2012/002
• Lead Sponsor: MSJ industries (Ceylon) (Pvt/ltd)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 20 August 2024

Recruitment & Eligibility

• Status: Terminated
• Sex: Not specified
• Target Recruitment: 60

Inclusion Criteria

All males and females with newly diagnosed Graves' thyrotoxicosis attending to the clinics mentioned above who are in the 18-70yrs age group
Criteria for diagnosis of Graves' disease - Signs and symptoms of Graves' hyperthyroidism; Diffusely enlarged goiter; Elevated thyroid hormones; Free T4 - Suppressed TSH levels enlarged goiter

Exclusion Criteria

- Other types of thyrotoxicosis (toxic multinodular goiter, toxic adenoma)
- Pregnancy
- Breast feeding
- Recurrent hyperthyroidism
- Patients who have undergone radio iodine treatment or treatment with Lugol's iodine
- Patients who are on medications known to interfere with thyroid functions – eg. lithium, amioradone, thyroxine, beta blockers, oral contraceptive pills, oestrogen containing agents, glucocorticoids
- Impaired liver functions
- Impaired renal functions

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
ormalization of free T4 [End of 4 weeks of treatment]<br>

Secondary Outcome Measures

Name	Time	Method
ormalization of serum TSH and FT3, rate of response of the drugs, reduction of the FT4 by a unit measurement of the drug [At 4, 8 and 12 weeks after starting treatment]<br>